糖尿病大鼠视网膜血管内皮生长因子与一氧化氮的变化

目的：探讨糖尿病大鼠视网膜血管内皮生长因子（VEGF）与一氧化氮（NO）的变化及其在糖尿病视网膜病变（DR）发生发展过程中的作用。方法：选择健康成年SD大鼠，随机分成正常对照组，糖尿病1月（DM1），糖尿病3月（DM3）和糖尿病5月（DM5）组，一次性腹腔注射链佐菌素（STZ）诱发糖尿病模型，应用免疫组织化学方法观察各组视网膜组织VEGF的表达情况，并检测各组视网膜组织中一氧化氮合酶（NOS）活性和NO含量变化。结果：3个月时，糖尿病大鼠视网膜VEGF表达增强，NOS活性增强，NO含量增高，5个月时，糖尿病大鼠视网膜表达进一步增强，而NOS活性开始减弱，NO含量减少，结论：糖尿病大鼠视网膜VEGF的过度表达和NOS活性，NO含量的变化在DR的发生发展过程中起重要作用。     

The effect of interleukin-1 on iron metabolism in rats

The effect of interleukin-1 on iron metabolism in rats was evaluated. Plasma iron decreased from 184 +/- 16 micrograms/dl (mean +/- SE) to 24 +/- 12 at 6 hours after interleukin-1 intramuscular administration in non-fasting rats and 109 +/- 6 micrograms/dl to 12 +/- 1 micrograms/dl in fasting rats, which was significantly lower than in control rats. Ferrokinetic studies showed a more rapid disappearance rate and lower iron turnover in interleukin-1-injected rats. The release of iron from the mononuclear phagocyte system to plasma was studied at 3 h after interleukin-1 administration. Although the percent of radioactivity in plasma of the total injected dose was 3.2 +/- 0.6% in interleukin-1, which was significantly lower than in the control rats (5.4 +/- 0.6%) at 9 h after intravenous injection of 59Fe chondroitin ferrous sulfate, there was no difference between the amount of 59Fe released from the mononuclear phagocyte system over the first 9 h in interleukin-1 and control rats. These data appear to imply that iron release is unimpaired but that, for some reason, there is an enhanced rate of clearance of the 59Fe once it has been released from the mononuclear phagocyte system into the plasma.     

A randomized,double‐blind,placebo controlled,multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome

Iron deficiency may exacerbate symptoms in the Restless Legs Syndrome (RLS). We investigated the effect of intravenous iron sucrose or placebo on symptoms in patients with RLS and mild to moderate iron deficit. Sixty patients with primary RLS (seven males, age 46 (9) years, S‐ferritin ≤45 μg/L) recruited from a cohort of 231 patients were randomly assigned in a 12‐months double‐blind, multi‐centre study of iron sucrose 1000 mg (n = 29) or saline (n = 31). The primary efficacy variable was the RLS severity scale (IRLS) score at week 11. Median IRLS score decreased from 24 to 7 (week 11) after iron sucrose and from 26 to 17 after placebo (P = 0.123, N.S. for between treatment comparison). The corresponding scores at week 7 were 12 and 20 in the two groups (P = 0.017). Drop out rate because of lack of efficacy at 12 months was 19/31 after placebo and 5/29 patients after iron sucrose (Kaplan–Meier estimate, log rank test P = 0.0006) suggesting an iron induced superior long term RLS symptom control. Iron sucrose was well tolerated. This study showed a lack of superiority of iron sucrose at 11 weeks but found evidence that iron sucrose reduced RLS symptoms both in the acute phase (7 weeks) and during long‐term follow up in patients with variable degree of iron deficiency. Further studies on target patient groups, dosing and dosing intervals are warranted before iron sucrose could be considered for treatment of iron deficient patients with RLS. © 2009 Movement Disorder Society     

Sildenafil relieves symptoms and normalizes motility in patients with oesophageal spasm: a report of two cases

Oesophageal spasm presents with dysphagia and chest pain. Current treatments are limited by poor efficacy and side effects. Studies in health and oesophageal dysmotility show that sildenafil reduces peristaltic pressure and velocity; however the clinical efficacy and tolerability in symptomatic oesophageal spasm remains uncertain. We provided open-label sildenafil treatment to two patients with severe, treatment resistant symptoms associated with oesophageal spasm. The effects of sildenafil on oesophageal function and symptoms were documented by high resolution manometry (HRM). Patients were followed up to assess the efficacy of maintenance treatment with sildenafil b.i.d. HRM revealed focal and diffuse spasm in the smooth muscle oesophagus that were associated with symptoms in both cases, especially on swallowing solids. Lower oesophageal sphincter function was normal. A therapeutic trial of 25-50 mg sildenafil suppressed oesophageal contraction almost completely for water swallows; however effective, coordinated peristalsis returned with reduced frequency of spasm for solid swallows. Dysphagia and chest pain resolved during the therapeutic trial and efficacy was maintained on maintenance treatment with 25-50 mg sildenafil b.i.d. without troublesome side effects. This report shows that sildenafil can improve oesophageal function and relieve dysphagia and chest pain in patients with oesophageal spasm in whom other treatments have failed.     

环氧丙烷对实验动物肝脏的影响

用环氧丙烷对大鼠进行实验性肝中毒研究的结果表明:一定剂量的环氧丙烷可引起大鼠血清GPT、GOT活性升高;病理形态学检查肝组织呈炎症反应。     

激素性股骨头坏死家兔血浆及软骨中一氧化氮含量的变化

[目的]探讨一氧化氮在激素性股骨头坏死发病中的作用.[方法]制作激素性股骨头坏死家兔模型后,在不同时期测定血浆及软骨中的一氧化氮含量,观察股骨头的组织学变化.[结果]激素性股骨头坏死家兔血浆和软骨中的一氧化氮含量均明显升高,股骨头髓腔中的脂肪细胞明显增多,骨小梁变细、稀疏及断裂,空骨陷窝明显增多.电子显微镜观察见骨细胞核染色质浓缩,体积缩小,胞浆中内质网及线粒体肿胀变性,粗面内质网上的核糖体脱落.[结论]一氧化氮参与激素性股骨头坏死的发病过程.     

iNOS在颅内囊性动脉瘤瘤壁中的表达及意义

目的探讨诱导性一氧化氮合酶（iNOs）在颅内囊性动脉瘤瘤壁中的表达及其意义。方法应用免疫组化染色和原位杂交染色技术检测iNOS在颅内囊性动脉瘤和正常动脉血管壁组织中的表达。结果所有脑动脉瘤标本中均可见iNOS表达，而正常脑动脉标本中则未见其表达：iNOS阳性表达部位主要在动脉瘤壁外膜和中膜的炎症浸润区的炎症细胞（如淋巴细胞、单核巨噬细胞）的胞浆内。结论动脉瘤的发生可能与局部iNOS过度表达，继而合成大量的NO有关。     

雌激素提高皮瓣存活面积的实验性研究

目的研究不同剂量雌激素对皮瓣存活面积的影响,并探讨其作用机制。方法新西兰白兔30只,随机分为A、B、O三组。在兔背作超长型皮瓣,其蒂部注射雌激素,三组间剂量不同。术后检测皮瓣血管内皮生长因子（VEGF）、一氧化氮（NO）、皮瓣存活面积（S）等指标。结果A组、B组皮瓣的NO、VEGF、S较O组增加;皮瓣存活面积S与VEGF表达、NO含量之间呈正相关。结论雌激素处理可使皮瓣VEGF表达上调、NO含量增加。